Gene · 8754
Papers1,799
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,799
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and functional experimental verification of efferocytosis-related diagnostic biomarkers for sepsis. | Int J Biochem Cell Biol | 2026 | 42777907 | PubTator, text mining | PubMed |
| Mechanisms related to increased susceptibility of the elderly lung to ventilator-induced lung injury: A scoping review. | Exp Gerontol | 2026 | 42735803 | PubTator, text mining | PubMed |
| Dissecting the Transcriptomic Profile of CD163+ Macrophages in Hepatocellular Carcinoma with VETC+ Angiogenesis Provides Potential Targets of Treatment. | Liver Cancer | 2026 | 42524682 | PubTator, text mining | PubMed |
| Collagen XVIIα1 in skin and hair aging: Mechanisms, stem cell niche regulation, and translational strategies. | J Dermatol Sci | 2026 | 42276855 | PubTator, text mining | PubMed |
| Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma. | Front Immunol | 2026 | 42266684 | PubTator, text mining | PubMed |
| Adam13 interacts with large protein complexes to regulate histone modification and gene expression. | Front Cell Dev Biol | 2026 | 42181688 | PubTator, text mining | PubMed |
| ADAM9: an updated view of its biology and pathology. | Mol Biol Rep | 2026 | 42171934 | PubTator, text mining | PubMed |
| A Theranostic Study of 177Lu-Labeled Anti-ADAM9 Antibody for the Treatment of Triple-Negative Breast Cancer. | Bioconjug Chem | 2026 | 42155035 | PubTator, text mining | PubMed |
| Evaluation of translational potential of mRNA vaccine candidate antigens for pancreatic cancer: a systematic review based on clinical evidence and stratified prioritization strategies. | Front Immunol | 2026 | 42131338 | PubTator, text mining | PubMed |
| M2 Macrophage membrane-mediated biomimetic nanoparticles carrying ADAM9 siRNA alleviate renal inflammation and fibrosis via the AKT/NF-κB pathway. | J Nanobiotechnology | 2026 | 42116024 | PubTator, text mining | PubMed |
| A Novel Partial EMT-Associated Transcriptomic Signature for Prognostic Stratification in Ovarian Cancer. | Oncol Res | 2026 | 42065049 | PubTator, text mining | PubMed |
| The Potential of A Disintegrin and Metalloproteinase (ADAM) Proteins as Clinically Relevant Biomarkers in Colorectal Cancer: A Comprehensive Analysis. | Cancers (Basel) | 2026 | 41976350 | PubTator, text mining | PubMed |
| ADAM9 in tumor biology: molecular functions, clinical implications, and therapeutic targeting. | Cell Mol Biol Lett | 2026 | 41933290 | PubTator, text mining | PubMed |
| Functional significance of miR-218 in lung cancer. | J Cancer Metastasis Treat | 2026 | 41924446 | PubTator, text mining | PubMed |
| Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies. | Curr Oncol | 2026 | 41892176 | PubTator, text mining | PubMed |
| Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review). | Int J Oncol | 2026 | 41860028 | PubTator, text mining | PubMed |
| Ugonin J Inhibits EMT and Migration in Prostate Cancer by Suppressing ADAM9 Expression. | Oncol Res | 2026 | 41799522 | PubTator, text mining | PubMed |
| Brain Metastasis in Nasopharyngeal Carcinoma: A Case Report. | Case Rep Oncol | 2026 | 41789432 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology. | Front Bioeng Biotechnol | 2026 | 41768137 | PubTator, text mining | PubMed |
| ADAM9 supports regulatory T cell stability through TGF-β-SMAD signaling and is reduced in systemic lupus erythematosus. | Clin Immunol | 2026 | 41765214 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8754/papers